STOCKWATCH
·
 Medicinal Chemicals and Botanical Products
Quarterly ResultMay 7, 2026, 06:03 AM

22nd Century Group Q1 Net Rev $4.1M; VLN Expansion Continues

AI Summary

22nd Century Group announced its first quarter 2026 results, with net revenues slightly increasing to $4.1 million from $3.5 million in Q4 2025, though net loss widened to $3.3 million and Adjusted EBITDA loss increased to $2.6 million. The company continues its VLN commercial expansion, aiming to reach over 5,000 retail outlets by the end of 2026, and is advancing its PMTA portfolio and licensing strategy to further penetrate the market with its reduced nicotine products.

Key Highlights

  • Targeting over 5,000 retail outlets for VLN products by end of 2026.
  • Q1 2026 net revenues were $4.1 million, up from $3.5 million in Q4 2025.
  • Q1 2026 net loss was $3.3 million, compared to $2.8 million in Q4 2025.
  • Q1 2026 Adjusted EBITDA loss was $2.6 million, compared to $2.4 million in Q4 2025.
  • Ended Q1 2026 with cash and cash equivalents of $9.5 million.
  • Cigarette net revenues were $2.8 million, up from $2.6 million in Q4 2025.
  • Filtered cigar net revenues were $0.9 million, up from $0.4 million in Q4 2025.
  • VLN cigarette net revenues were $0.0 million in Q1 2026, following initial stocking orders in Q4 2025.
XXII
Medicinal Chemicals and Botanical Products
22nd Century Group, Inc.

Price Impact